AVEO

AVEO Pharmaceuticals, Inc. Press Releases

$0.82
*  
0.0059
0.72%
Get AVEO Alerts
*Delayed - data as of Dec. 24, 2014  -  Find a broker to begin trading AVEO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
11/11/2014 6:42:00 AM - Business Wire
▼-10.87 % Price Change since this news event. The Volume Ratio is 9.51.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AVEO Oncology Reports Third Quarter 2014 Financial Results
11/5/2014 4:16:00 PM - Business Wire
▼-13.68 % Price Change since this news event. The Volume Ratio is 4.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
9/29/2014 6:45:00 AM - Business Wire


AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
9/29/2014 6:00:00 AM - Business Wire